EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies

Chiara Tommasi iD, Giulia Airò iD, Fabiana Pratticò, Irene Testi, Matilde Corianò, Benedetta Pellegrino, Nerina Denaro iD, Laura Demurtas, Mariele Dessì, Sara Murgia, Giovanni Mura, Demi Wekking iD und 3 weitere

Journal of Clinical Medicine · 24.03.2024 · 13 (7) · 1873

DOI: 10.3390/jcm13071873 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.03.2024. Verfasst von Chiara Tommasi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology and Breast Unit, University Hospital of Parma, 43126 Parma, Italy. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care options both in neoadjuvant/adjuvant settings and in advanced disease. Additionally, we focus on new trials and drugs for HR-positive/HER2-positive breast cancer and the new entity: HER2-low breast cancer.

Schlagwörter

Stichwörter der Autor:innen

HER2HER2 blockageendocrine therapyestrogen receptorhormone receptor positive HER2-positive breast cancer

Autor:innen und Institutionen

  • Medical Oncology and Breast Unit, University Hospital of Parma, 43126 Parma, Italy.
  • Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy.
  • GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), 43100 Parma, Italy.
  • Medical Oncology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy.
  • Medical Oncology, AOU Cagliari, Policlinico Duilio Casula, 09042 Monserrato, Italy.
  • Medical Oncology, University of Cagliari, 09124 Cagliari, Italy.

ORCID-Profile: Chiara Tommasi, Giulia Airò, Nerina Denaro, Demi Wekking, Mario Scartozzi, Antonino Musolino

Zitieren

APA

Tommasi, C., Airò, G., Pratticò, F., Testi, I., Corianò, M., Pellegrino, B., Denaro, N., Demurtas, L., Dessì, M., Murgia, S., Mura, G., Wekking, D., Scartozzi, M., Musolino, A., & Solinas, C. (2024). Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies. Journal of Clinical Medicine, 13(7), 1873. https://doi.org/10.3390/jcm13071873

Vancouver

Tommasi C, Airò G, Pratticò F, Testi I, Corianò M, Pellegrino B, et al. Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies. Journal of Clinical Medicine. 2024;13(7):1873. doi:10.3390/jcm13071873

BibTeX
@article{Tommasi2024,
  author = {Tommasi, Chiara and Airò, Giulia and Pratticò, Fabiana and Testi, Irene and Corianò, Matilde and Pellegrino, Benedetta and Denaro, Nerina and Demurtas, Laura and Dessì, Mariele and Murgia, Sara and Mura, Giovanni and Wekking, Demi and Scartozzi, Mario and Musolino, Antonino and Solinas, Cinzia},
  title = {Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {7},
  pages = {1873},
  doi = {10.3390/jcm13071873}
}
Kostenlos starten →